GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Gross Margin %

Venus Medtech (Hangzhou) (HKSE:02500) Gross Margin % : 79.72% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Venus Medtech (Hangzhou)'s Gross Profit for the six months ended in Dec. 2023 was HK$205.6 Mil. Venus Medtech (Hangzhou)'s Revenue for the six months ended in Dec. 2023 was HK$257.9 Mil. Therefore, Venus Medtech (Hangzhou)'s Gross Margin % for the quarter that ended in Dec. 2023 was 79.72%.

Warning Sign:

Venus Medtech (Hangzhou) Inc gross margin has been in long-term decline. The average rate of decline per year is -1.9%.


The historical rank and industry rank for Venus Medtech (Hangzhou)'s Gross Margin % or its related term are showing as below:

HKSE:02500' s Gross Margin % Range Over the Past 10 Years
Min: 77.25   Med: 82.33   Max: 85.81
Current: 79.21


During the past 7 years, the highest Gross Margin % of Venus Medtech (Hangzhou) was 85.81%. The lowest was 77.25%. And the median was 82.33%.

HKSE:02500's Gross Margin % is ranked better than
89.14% of 801 companies
in the Medical Devices & Instruments industry
Industry Median: 52.83 vs HKSE:02500: 79.21

Venus Medtech (Hangzhou) had a gross margin of 79.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Venus Medtech (Hangzhou) was -1.90% per year.


Venus Medtech (Hangzhou) Gross Margin % Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Gross Margin % Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 83.45 82.33 77.99 77.25 79.21

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.16 78.19 76.25 78.73 79.72

Competitive Comparison of Venus Medtech (Hangzhou)'s Gross Margin %

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Gross Margin % distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Gross Margin % falls into.



Venus Medtech (Hangzhou) Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Venus Medtech (Hangzhou)'s Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=425.7 / 537.453
=(Revenue - Cost of Goods Sold) / Revenue
=(537.453 - 111.749) / 537.453
=79.21 %

Venus Medtech (Hangzhou)'s Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=205.6 / 257.873
=(Revenue - Cost of Goods Sold) / Revenue
=(257.873 - 52.291) / 257.873
=79.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Venus Medtech (Hangzhou)  (HKSE:02500) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Venus Medtech (Hangzhou) had a gross margin of 79.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Venus Medtech (Hangzhou) Gross Margin % Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines